Navigation Links
InspireMD Hires Vice President of Corporate Development

TEL AVIV, Israel, April 19, 2013 /PRNewswire/ --

InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) said Gwen K. Bame has joined the Company as Vice President of Corporate Development, reporting directly to Alan Milinazzo , President and CEO.

    "This is a new position created to strengthen our executive team with a clear focus on executing strategic programs and partnerships designed to meet our ambitious global growth objectives," said Mr. Milinazzo.  "Gwen has the right blend of industry and management experience and we are delighted to welcome her to InspireMD."

    Ms. Bame's responsibilities will include identifying and negotiating in/out licensing agreements, analyzing strategic partnerships and structuring of joint ventures on a worldwide basis.

    Ms. Bame joined Covidien in 2009 upon its acquisition of Aspect Medical Systems, where she held various sales and marketing leadership positions during her tenure. She led significant market development programs directly and via strategic partnerships which drove adoption of the BIS technology.

    Prior to her time at Covidien, Ms. Bame spent 12 years with Boston Scientific in the cardiology business in sales, marketing and corporate accounts. During her career at BSC, she negotiated roughly $350 million in contracted business across multiple business units.

About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Forward-looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q.  Investors and security holders are urged to read these documents free of charge on the SEC's web site at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For additional information:
InspireMD Desk
Redington, Inc.

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Berman Joins InspireMD Board
2. InspireMD Postpones $40 Million Registered
3. InspireMD Reports 2012 Fiscal Year Results
4. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
5. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
6. InspireMD Appoints Dr. James Barry to Its Board of Directors
7. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
8. AFcell Medical Hires Chief Operating Officer
9. Prova Education Hires Oncology Expert Alana Brody to Further Expand its Oncology Education and Opportunities
10. PI hires William Culpi as Engineering Chief - PI miCos USA Products by PI USA
11. InSoCal CONNECT Hires Technology Talent Executive Carol Caldwell
Post Your Comments:
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/23/2016)... 23, 2016 adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
Breaking Biology Technology:
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):